A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Atai Life Sciences N.V. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 45,800 shares of ATAI stock, worth $52,211. This represents 0.0% of its overall portfolio holdings.

Number of Shares
45,800
Previous 20,900 119.14%
Holding current value
$52,211
Previous $41,000 46.34%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$1.27 - $2.6 $31,623 - $64,740
24,900 Added 119.14%
45,800 $60,000
Q1 2024

May 15, 2024

SELL
$1.5 - $2.19 $60,750 - $88,695
-40,500 Reduced 65.96%
20,900 $41,000
Q4 2023

Feb 14, 2024

SELL
$1.04 - $1.55 $47,944 - $71,455
-46,100 Reduced 42.88%
61,400 $86,000
Q3 2023

Nov 14, 2023

SELL
$1.27 - $2.28 $77,216 - $138,624
-60,800 Reduced 36.13%
107,500 $138,000
Q2 2023

Aug 14, 2023

SELL
$1.44 - $2.19 $423,072 - $643,422
-293,800 Reduced 63.58%
168,300 $289,000
Q1 2023

May 15, 2023

BUY
$1.17 - $2.7 $34,281 - $79,110
29,300 Added 6.77%
462,100 $836,000
Q4 2022

Feb 14, 2023

BUY
$2.38 - $3.55 $429,352 - $640,420
180,400 Added 71.47%
432,800 $1.15 Million
Q3 2022

Nov 14, 2022

BUY
$3.14 - $4.87 $176,468 - $273,694
56,200 Added 28.64%
252,400 $835,000
Q2 2022

Aug 15, 2022

BUY
$3.03 - $5.32 $349,965 - $614,460
115,500 Added 143.12%
196,200 $714,000
Q1 2022

May 16, 2022

BUY
$4.66 - $7.66 $90,404 - $148,604
19,400 Added 31.65%
80,700 $411,000
Q4 2021

Feb 14, 2022

BUY
$6.82 - $17.8 $418,066 - $1.09 Million
61,300 New
61,300 $468,000

Others Institutions Holding ATAI

About ATAI Life Sciences N.V.


  • Ticker ATAI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 165,875,008
  • Market Cap $189M
  • Description
  • Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment o...
More about ATAI
Track David A. Siegel's Portfolio

Track David A. Siegel Portfolio

Follow David A. Siegel (Two Sigma Advisers, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.